Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA
Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit for the preparation...
Read more
Latest News
Category: ASX
Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit for the preparation...
Read more
Telix Pharmaceuticals Provides Investor Briefing: Our Asian...
Read more
Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China...
Read more
Telix Pharmaceuticals provides its Activity Report and Appendix 4C for the quarter ending 30th September 2020, and Q3 2020 sales update for its prostate cancer imaging...
Read more
Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging of...
Read more
Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for the preparation of...
Read more
Telix announces it has entered into a strategic collaboration agreement with Varian Medical...
Read more
Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging...
Read more
Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of multiple...
Read more
Telix will hold an investor conference call to present the Company’s H1 2020 financial results together with an update on Telix’s...
Read more